Abstract
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
Original language | English (US) |
---|---|
Pages (from-to) | 487-489 |
Number of pages | 3 |
Journal | Med |
Volume | 5 |
Issue number | 6 |
DOIs |
|
State | Published - Jun 14 2024 |
ASJC Scopus subject areas
- General Medicine